Pharma News

The preliminary analysis of Adverse Drug Reaction (ADR) from the PvPI database reveals that Tacrolimus is associated with Gingival Hypertrophy.

CDSCO issues alerts against Adsorba Hemoperfusion Cartridge 300 C and Adsorba 300 C APAC due to the potential presence of particulate matter within the cartridge.

Baxter has issued a recall notice for various batches of Adsorba Hemoperfusion Cartridge 300 C and Adsorba 300 C APACdue to presence of particulate matter within the cartridge which may lead to serious adverse effects in the patients.

Medical interns from India studies adverse Events after COVID-19 Vaccine in Indian Population. The study determined the incidence of adverse events experienced by participants post-COVID-19 vaccination and compared adverse events in participants receiving Covishield and Covaxin.

There are a lot of published studies on the efficacy of these vaccines but little is known about adverse events following vaccination outside of clinical trial data.

Nevro Corp and Boston Scientific Corp announced today that they have reached a settlement in their ongoing intellectual property litigations that gives Boston Scientific the freedom to operate using the features and capabilities embodied in its current line of products for frequencies below 1,500 Hz, and gives Nevro the freedom to operate using the features and capabilities embodied in its current line of products.

Upadacitinib significantly improved the signs and symptoms of non-radiographic axial spondyloarthritis compared with placebo at week 14. Upadacitinib, sold under the brand name Rinvoq by Abbvie.

Upadacitinib, a Janus kinase inhibitor, has been shown to be effective in patients with ankylosing spondylitis. Researchers aimed to assess the efficacy and safety of upadacitinib in non-radiographic axial spondyloarthritis.

Pfizer Inc and BioNTech SE announced that the companies have initiated a randomized, active-controlled, observer-blind, Phase 2 study to evaluate the safety, tolerability, and immune response of an enhanced COVID-19 mRNA-based vaccine candidate at a 30 µg dose level. This next-generation bivalent COVID-19 vaccine candidate, BNT162b5, consists of RNAs encoding enhanced prefusion spike proteins for the SARS-CoV-2 ancestral strain (wild-type) and an Omicron variant.

The U.S. Food and Drug Administration prioritizes the health and safety of American consumers and patients as well as animals and uses a variety of tools for the appropriate oversight of FDA-regulated products and establishments. With manufacturers and supply chains dispersed around the world, the FDA works to help ensure that only products that meet our rigorous standards reach the U.S. marketplace.

Colorectal tumors are swarming with white blood cells, but whether these cells help or hinder the cancer is hotly debated. While some studies have shown that white blood cells heroically restrict tumor growth and combat colorectal cancer, equally compelling evidence casts the white blood cells as malignant co-conspirators bolstering the tumor and helping it spread.

Natco Pharma Limitedannounces that the U.S. Food and Drug Administration has granted approval to its partner Breckenridge Pharmaceutical Inc’s Abbreviated New Drug Application for Cabazitaxel Intravenous Powder (generic for Jevtana Kit) for the 60mg/1.5mL (40mg/mL) strength.